D.B. Root & Company LLC Reduces Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

D.B. Root & Company LLC reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 30.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 750 shares of the company’s stock after selling 328 shares during the period. D.B. Root & Company LLC’s holdings in IDEXX Laboratories were worth $416,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Gotham Asset Management LLC boosted its holdings in shares of IDEXX Laboratories by 79.9% in the third quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock valued at $7,620,000 after acquiring an additional 7,741 shares during the period. NewEdge Wealth LLC increased its stake in IDEXX Laboratories by 30.4% in the third quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock valued at $279,000 after purchasing an additional 149 shares during the period. Mitchell Capital Management Co. raised its holdings in shares of IDEXX Laboratories by 1.3% in the third quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock valued at $2,786,000 after buying an additional 79 shares during the last quarter. AEGON ASSET MANAGEMENT UK Plc acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $37,291,000. Finally, Whittier Trust Co. of Nevada Inc. boosted its stake in shares of IDEXX Laboratories by 108.6% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 73 shares of the company’s stock worth $32,000 after buying an additional 38 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock valued at $24,871,960 in the last ninety days. Corporate insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on IDXX. The Goldman Sachs Group upped their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Barclays increased their price target on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Friday, January 5th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Finally, BNP Paribas began coverage on shares of IDEXX Laboratories in a report on Thursday, December 7th. They issued an “outperform” rating and a $602.00 target price on the stock. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $591.50.

Check Out Our Latest Report on IDXX

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $530.72 on Monday. The firm’s fifty day simple moving average is $547.66 and its 200-day simple moving average is $500.88. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. The stock has a market cap of $44.10 billion, a PE ratio of 52.70, a price-to-earnings-growth ratio of 2.91 and a beta of 1.27. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last issued its earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The company had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. During the same period in the prior year, the business posted $2.05 earnings per share. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. Analysts expect that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Featured Stories

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.